Praxedis Martin
YOU?
Author Swipe
View article: Development of anti-murine IL-18 binding protein antibodies to stimulate IL-18 bioactivity
Development of anti-murine IL-18 binding protein antibodies to stimulate IL-18 bioactivity Open
Interleukin (IL)-18 is an immunoregulatory cytokine that acts as a potent inducer of T helper 1 and cytotoxic responses. IL-18 activity is regulated by its decoy receptor IL-18 binding protein (IL-18BP), which forms a high-affinity complex…
View article: IL-1 Family Antagonists in Mouse and Human Skin Inflammation
IL-1 Family Antagonists in Mouse and Human Skin Inflammation Open
Interleukin (IL)-1 family cytokines initiate inflammatory responses, and shape innate and adaptive immunity. They play important roles in host defense, but excessive immune activation can also lead to the development of chronic inflammator…
View article: β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion
β Cell-Specific Deletion of the IL-1 Receptor Antagonist Impairs β Cell Proliferation and Insulin Secretion Open
Interleukin-1 receptor antagonist (IL-1Ra) is elevated in the circulation during obesity and type 2 diabetes (T2D) but is decreased in islets from patients with T2D. The protective role of local IL-1Ra was investigated in pancreatic islet …
View article: Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice
Unopposed IL-18 signaling leads to severe TLR9-induced macrophage activation syndrome in mice Open
Key Points Endogenous IL-18BP is critical to prevent severe MAS on repetitive TLR9 stimulation. IL-18BP deficiency is associated with elevated plasma levels of free IL-18 and an enhanced IFN-γ molecular signature in TLR9-induced MAS.
View article: Atherosclerosis severity is not affected by a deficiency in IL‐33/ST2 signaling
Atherosclerosis severity is not affected by a deficiency in IL‐33/ST2 signaling Open
Interleukin (IL)‐33 is a cytokine of the IL‐1 family, which signals through the ST2 receptor. Previous work demonstrated that the systemic administration of recombinant IL‐33 reduces the development of atherosclerosis in apolipoprotein E‐d…